<table class="naaccr-summary-table naaccr-borders">
  <tr>
    <th class="naaccr-summary-header naaccr-borders">Item #</th>
    <th class="naaccr-summary-header naaccr-borders">Length</th>
    <th class="naaccr-summary-header naaccr-borders">Source of Standard</th>
    <th class="naaccr-summary-header naaccr-borders">Year Implemented</th>
    <th class="naaccr-summary-header naaccr-borders">Version Implemented</th>
    <th class="naaccr-summary-header naaccr-borders">Year Retired</th>
    <th class="naaccr-summary-header naaccr-borders">Version Retired</th>
  </tr>
  <tr>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">3956</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">1</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">SEER</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">2022</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">22</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
  </tr>
</table>

<br/><strong>NAACCR XML</strong>: Tumor.p16<br/><br/>


<div class='content chap10-para-head'><strong><strong>Description</strong></strong></div><div class='content chap10-para'>The p16 biomarker is over-expressed (produced) in response to HPV.  It is therefore a surrogate marker for HPV disease.</div><div class='content chap10-para-head'><strong><strong>Rationale</strong></strong></div><div class='content chap10-para'>Patients with HPV have a different survival or outcome so it is important to be able to distinguish this by documenting the p16 results. Testing is performed by immunohistochemistry (IHC) which is inexpensive and has near universal availability. It has an easily standardized interpretation. HPV testing is usually performed through DNA testing which is more expensive and less widely available. HPV testing also has technically more variability with the interpretation.</div><div class='content chap10-para'>p16 is a tumor suppressor protein also known as cyclin-dependent kinase inhibitor 2A. The p16 biomarker is over-expressed (produced) in response to HPV. It is therefore a surrogate marker for HPV disease.</div><div class='content chap10-para'><strong>Codes</strong></div><div class='content chap10-para'><table><tr class='code-row'><td class='code-nbr'>0</td><td class='code-desc'>p16 Negative; Nonreactive </td></tr><tr class='code-row'><td class='code-nbr'>1</td><td class='code-desc'>p16 Positive; Diffuse, Strong reactivity </td></tr><tr class='code-row'><td class='code-nbr'>8</td><td class='code-desc'>Not applicable: Information not collected for this case<br/>
(If this time is required by your standard setter, use of code 8 will result in an edit error).
</td></tr><tr class='code-row'><td class='code-nbr'>9</td><td class='code-desc'>Not tested for p16; Unknown</td></tr><tr class='code-row'><td class='code-nbr'>Blank</td><td class='code-desc'>Diagnosis year prior to 2021</td></tr><tr class='code-row'><td class='code-nbr'></td><td class='code-desc'> </td></tr></table></div><div class='content chap10-para mark-changed'><div>Note: See the 

<a href="https://apps.naaccr.org/ssdi/list/?_gl=1*111s1ff*_ga*NTAyNDk1MDUwLjE1OTI5Mzk3MDY.*_ga_ZGX07SVHJF*MTY1NDU0NDUzMy40LjEuMTY1NDU0NDcwNi4w&amp;_ga=2.89925727.598791132.1654524231-502495050.1592939706">SSDI Manual</a> for coding instructions.</div><div>Anus schema added/ Please note for CCCR p16 for Cervix changed from "." to RS* retroactive to 2021&nbsp;&nbsp;</div></div>